A Mendelian randomization study showed that the immunomodulatory effects of PCSK9 could have an effect on autoimmune diseases, and that PCSK9 inhibitors significantly reduced the risk of SLE but increased the risk of asthma and Crohn’s disease (372). This evidence concerns the gene PCSK9 and autoimmune disease.